Androgen Insensitivity Syndrome is a genetic condition where a person with one X and one Y chromosome (46,XY) makes typical amounts of male hormones (androgens) but the body’s cells cannot “hear” those signals well or at all. Because the cells don’t respond to androgens, sex development before birth and during puberty can follow a more typically female path, a mixed path, or a mostly male path with some differences. AIS is a spectrum: from complete insensitivity (body does not respond to androgens) to partial (responds a little) to mild (responds mostly but not fully). MedlinePlus+2NCBI+2
AIS is X-linked, meaning the gene involved (the androgen receptor or AR gene) sits on the X chromosome. Most people with AIS have a normal level of testosterone, but because the receptor does not work properly, the hormone’s message cannot produce its usual effects on the body’s tissues. NCBI+1
Other names
AIS is also called Androgen Receptor (AR) Defect, Androgen Resistance, 46,XY Disorder/Difference of Sex Development due to AR, and historically Testicular Feminization (an older term that many now avoid). All of these terms refer to difficulties in the body responding to androgens because of changes in the AR gene or its function. NCBI+1
Types of AIS
Complete AIS (CAIS): The body does not respond to androgens. People are typically born with external female anatomy, have undescended testes (often in the groin or abdomen), no uterus or fallopian tubes, and a shorter vagina that ends blindly. Puberty brings breast development from aromatization of testosterone to estrogen, but little or no pubic or underarm hair. Primary amenorrhea (no periods) is common because there is no uterus. NCBI+1
Partial AIS (PAIS): The body responds partly. Genital appearance at birth can be varied (sometimes called “ambiguous”), such as hypospadias (opening of the urethra on the underside of the penis), a smaller penis, or a large clitoris; one or both testes may be undescended. Puberty may bring gynecomastia (breast growth), less facial/body hair, and fertility challenges. NCBI+1
Mild AIS (MAIS): The body responds mostly, but not fully. People typically look male at birth. Later, they may have reduced body hair, infertility, or gynecomastia. Some have normal genital appearance but reduced androgen effects in specific tissues. NCBI
Causes
AIS is caused by problems in the androgen receptor (AR) gene that prevent cells from using androgens effectively. Below are different ways that problem can happen. Each item is a distinct, documented mechanism or pathway contributing to AR dysfunction.
Missense mutations in the ligand-binding domain (LBD): A single “letter” change alters the hormone-binding pocket, so testosterone or dihydrotestosterone (DHT) cannot bind normally. This often causes PAIS or CAIS. NCBI+1
Missense mutations in the DNA-binding domain (DBD): The receptor can’t grip DNA well, so androgen-controlled genes aren’t turned on. Severity varies by exact site. Endocrine Society
Missense mutations in the N-terminal (activation) domain: This region recruits helper proteins; changes here can blunt the “volume” of the androgen signal. PMC
Nonsense mutations: A “stop” signal appears too early, making a short, non-working receptor; this often leads to CAIS. Endocrine Society
Frameshift mutations: Small insertions/deletions shift the reading frame and usually destroy receptor function. Endocrine Society
Splice-site mutations: The cell misprocesses AR gene “exons,” leaving out or mis-including pieces, so the receptor is faulty. PMC
Large deletions in the AR gene: Big missing segments, sometimes including the LBD, can cause CAIS. NCBI+1
Large duplications/rearrangements: Extra or misplaced gene segments disrupt normal AR structure or expression. Translational Andrology and Urology
Promoter/regulatory variants: Changes in on/off switches reduce AR gene expression, lowering receptor amounts in cells. PMC
Defects in nuclear localization signals: The receptor can’t get into the nucleus efficiently to reach DNA. PMC
Defective interaction with co-activators/co-repressors: Even if hormone binds, poor coupling to helper proteins weakens gene activation. PMC
Abnormal receptor folding/chaperone interactions (e.g., HSP90 pathways): Misfolded receptor is unstable or degraded. PMC
Post-zygotic (mosaic) AR mutations: Some cells carry the mutation while others don’t, causing mixed tissue responses. PMC
De novo mutations: A new AR change appears for the first time in the child, not inherited from a parent. MedlinePlus
X-linked inheritance from a carrier mother: The AR variant is passed through the X chromosome to a 46,XY child. NCBI
CAG repeat length extremes in AR (rare AIS-like presentations): Unusual lengths can influence receptor activity; very long repeats reduce activity. (This is uncommon in classic AIS but illustrates AR activity modulation.) PMC
Mutations that impair dimerization: The receptor works as a pair; defects can block pairing and gene control. PMC
Mutations that block receptor turnover/stability: If the receptor breaks down too fast or is trapped in the cytoplasm, signaling drops. PMC
Gene conversion or complex rearrangements at AR locus: Unusual DNA events can scramble AR coding regions. Translational Andrology and Urology
Unresolved/unknown AR-negative cases: Rarely, a person has an AIS-like picture without a detectable AR coding variant; deep intronic or structural variants or rare pathway genes may be involved. Research is ongoing. ScienceDirect
Common signs and symptoms
Primary amenorrhea (no periods): In CAIS, there is no uterus, so periods do not occur despite normal breast development at puberty. NCBI
Typical female external anatomy at birth (CAIS): Babies look like girls, even though chromosomes are 46,XY. MedlinePlus
Undescended testes (inguinal or abdominal): Gonads may be felt as “lumps” in the groin or found on imaging. NCBI
Short, blind-ending vagina (often in CAIS): Vaginal length may be shorter, with no cervix or uterus. NCBI
Little or no pubic/underarm hair (CAIS): Because hair follicles need androgen signaling. NCBI
Breast development at puberty (CAIS): Testosterone converts to estrogen, which drives breast growth. NCBI
Hernia in infancy/childhood: A groin hernia in a “girl” may hide a testis. NCBI
Ambiguous genitalia (PAIS): Genital appearance can be mixed; hypospadias or small penis may be seen. NCBI
Gynecomastia in adolescence (PAIS/MAIS): Breast tissue may grow due to hormone balance and partial resistance. NCBI
Reduced facial/body hair (PAIS/MAIS): Hair growth depends on androgen action. NCBI
Infertility or reduced fertility: Androgen signaling is key for sperm production and reproductive tract development. NCBI
Tallish height compared with female peers (CAIS, sometimes): Growth patterns can differ because of hormone effects and timing. NCBI
Lower bone density risk over time (after gonad removal without adequate hormones): Lifelong sex-steroid support is important for bone health. ScienceDirect
Psychosocial stress: Puberty, diagnosis, and decisions about care can be stressful; supportive care helps. NCBI+1
Gonadal tumor risk over the lifespan: Risk is low in early childhood in CAIS but may rise with age; risk patterns differ by AIS subtype. PMC+2archivesofmedicalscience.com+2
Diagnostic Tests
A) Physical examination (what the clinician looks for)
General newborn/child exam: The clinician notes genital appearance, body proportions, and any groin masses; in CAIS, external anatomy looks typically female despite 46,XY chromosomes. NCBI
Pubertal exam: Checks breast development, body and facial hair, and growth pattern to see how puberty is progressing and whether androgen effects are reduced. NCBI
Inguinal exam for hernia or gonads: Feeling a firm oval structure in the groin of a phenotypic girl suggests an undescended testis. NCBI
Pelvic exam (age-appropriate, gentle): Looks for vaginal length and whether a cervix is present; in CAIS there is usually a short vagina and no cervix. NCBI
Skin/hair exam: Sparse pubic/axillary hair in CAIS is a common clue. NCBI
Breast/chest exam: Gynecomastia in partial/mild AIS or normal breast development in CAIS can guide testing. NCBI
B) Manual or bedside assessments (simple hands-on measurements)
Staged genital scoring (e.g., Prader or Quigley scales): Clinicians use standardized scales to document how masculinized the genitalia are; this helps classify CAIS, PAIS, or MAIS. PMC
Vaginal measurement (with consent, age-appropriate): Measures vaginal length to plan counseling and future care. NCBI
Testis palpation and position mapping: Locates gonads to guide imaging or surgical planning. NCBI
Blood pressure/anthropometrics: Part of general endocrine assessment; helps in safe planning of hormone care later. NCBI
C) Laboratory and pathological tests (the core of diagnosis)
Karyotype (chromosome test): Confirms 46,XY status. This is basic in any difference of sex development evaluation. NCBI
Hormone panel (LH, FSH, testosterone, DHT, estradiol): In AIS, testosterone is often normal or high for age/sex, LH can be high, and DHT is usually normal; the T/DHT ratio is not elevated as in 5-alpha-reductase deficiency. NCBI+1
AMH and inhibin B: Help confirm functioning testicular tissue in children and guide staging. NCBI
AR gene sequencing (next-generation sequencing): Looks for missense, nonsense, splice, or frameshift variants that explain AIS. This is the main confirmatory test today. NCBI+1
Deletion/duplication analysis (e.g., MLPA or exome CNV): Detects large AR gene deletions or duplications missed by routine sequencing. NCBI
Functional AR testing in genital skin fibroblasts (specialized centers): Measures receptor binding and gene activation in the lab when DNA results are unclear. NCBI
Pathology of gonadal tissue (if surgery/biopsy is performed): Histology can show testicular tissue features, Sertoli-cell changes, or rare premalignant lesions. PMC
D) Electrodiagnostic tests (not routinely used for AIS)
Note: There are no AIS-specific electrodiagnostic tests (like EEG/EMG) used to diagnose AIS. If a person has separate nerve or muscle concerns, nerve studies may be done, but they do not diagnose AIS. Diagnosis relies on genetics, hormones, and imaging. NCBI
E) Imaging tests (to see internal anatomy safely)
Pelvic/inguinal ultrasound: Looks for testes in the groin/abdomen, checks for uterus or cervix (usually absent in CAIS), and measures vaginal length indirectly. NCBI
MRI of pelvis/abdomen (when needed): Gives a clear map of gonad location and internal structures to guide care decisions. NCBI
DXA scan for bone density (later care): After gonad removal, appropriate estrogen therapy is important for bones; DXA monitors bone health over time. ScienceDirect
Non-pharmacological treatments (therapies & others)
Multidisciplinary DSD team care – coordinated visits with endocrinology, gynecology/urology, psychology, genetics, and specialized nursing improve understanding, reduce anxiety, and support shared decisions over time. Purpose: whole-person care. Mechanism: integrated expertise and counseling. Oxford Academic
Genetic counseling – explains the AR gene change, inheritance (often X-linked), recurrence risk, and options for relatives who want testing. Purpose: informed family planning. Mechanism: risk assessment and education. MedlinePlus
Psychological support & peer groups – common needs include coping with diagnosis, identity, intimacy, and stigma. Professional counseling and peer communities improve quality of life. Purpose: mental well-being. Mechanism: evidence-based psychotherapy and social support. NCBI
Informed decision-making about gonads – CAIS has low prepubertal tumor risk; many teams delay gonadectomy until after puberty so natural puberty can occur, then revisit choices with the patient. Purpose: balance tumor risk with benefits of endogenous puberty. Mechanism: staged, consent-based counseling. e-apem.org+1
Surveillance when gonads retained – if the person chooses to keep gonads, teams discuss regular clinical review and imaging (e.g., ultrasound/MRI) to watch for changes. Purpose: early detection. Mechanism: risk-based monitoring pathways. PMC
Vaginal self-dilation (first-line for a short vagina) – gentle, structured use of dilators can lengthen the vagina without surgery, with >90–96% success when the person is ready and supported. Purpose: comfortable intercourse if desired. Mechanism: tissue expansion by gradual pressure. ACOG+1
Sexual-health education – practical advice on lubrication, pacing, comfort, consent, and pleasure; addresses dyspareunia and expectations. Purpose: satisfying, safe sex. Mechanism: skills and knowledge. ACOG
Pelvic floor physical therapy – teaches relaxation and coordination for comfort with dilation or intercourse; helpful for vaginismus. Purpose: reduce pain, improve function. Mechanism: biofeedback and graded exposure. PMC
Bone-health lifestyle plan – weight-bearing/resistance exercise, fall-prevention, not smoking, and limiting alcohol to protect bone density, which can be low in AIS. Purpose: reduce osteoporosis risk. Mechanism: mechanical loading and risk-factor reduction. PMC+1
Nutrition coaching for bones – food-first calcium and vitamin D, protein adequacy; supplements only to fill gaps per guidelines. Purpose: support bone remodeling. Mechanism: optimize mineral and protein intake. Bone Health & Osteoporosis Foundation
Sunlight & vitamin D literacy – safe sun practices and vitamin D intake aligned with current endocrine guidance. Purpose: maintain 25(OH)D in a healthy range. Mechanism: skin synthesis + diet/supplements per need. Endocrine Society+1
Fertility and family-building counseling – CAIS lacks eggs/uterus, so options are adoption or gestational carrier with donor eggs if desired. Purpose: plan pathways to parenting. Mechanism: reproductive counseling and legal guidance. PubMed
Body-image and identity support – structured sessions normalize variation, address hair pattern, chest, genital differences, and social issues. Purpose: self-esteem and well-being. Mechanism: CBT, ACT, and affirming care. NCBI
Transition-of-care planning – smooth handoff from pediatric to adult services to maintain hormone care, bone checks, and sexual health follow-up. Purpose: continuity and safety. Mechanism: planned transition protocols. Oxford Academic
Cancer-risk education – clear, age-appropriate explanation that CAIS tumor risk is low before puberty and increases with age, with shared planning for surveillance or surgery. Purpose: reduce fear, guide choices. Mechanism: evidence-based risk framing. e-apem.org
Pain and hernia care – inguinal hernias or gonadal pain are managed conservatively or surgically depending on symptoms. Purpose: comfort and safety. Mechanism: individualized surgical consultation. Children’s Hospital of Philadelphia
Education on medications & adherence – practical coaching to take estrogen consistently after gonadectomy to protect bones and well-being. Purpose: prevent osteopenia and symptoms. Mechanism: adherence strategies. PMC
Community and advocacy connections – linking with AIS/DSD support groups improves knowledge and resilience. Purpose: reduce isolation. Mechanism: peer modeling and shared experience. Endocrine Society
General preventive care – routine vaccines, STI prevention, cardiovascular risk screening (as with any adult on hormones), and cervical screening is not needed when there is no cervix. Purpose: overall health. Mechanism: age-appropriate prevention. NCBI
Shared documentation – providing letters that clearly explain AIS can reduce confusion in emergency or travel situations. Purpose: smoother care journeys. Mechanism: concise medical summaries. Oxford Academic
Drug treatments
Transdermal 17β-estradiol (patch) – a common first-choice after gonadectomy or if endogenous estrogen is inadequate. Purpose: sustain feminization, protect bone, reduce vasomotor symptoms. Mechanism: physiologic estradiol delivery; some data suggest transdermal may have metabolic advantages. Typical adult maintenance often equals 50–100 μg/day patch, titrated. The Lancet
Oral 17β-estradiol – alternative to patches for estrogen replacement; dose individualized (e.g., 1–4 mg/day equivalents). Purpose/mechanism: as above. PMC
Estradiol gel – topical route for those preferring gels; titrated to clinical targets. Purpose: flexible dosing without first-pass liver effect. Mechanism: transdermal absorption. The Lancet
Ethinyl estradiol – effective but generally less favored long-term compared with 17β-estradiol in many centers due to hepatic effects; may be used in some puberty-induction protocols. Purpose: puberty induction/maintenance where chosen. Mechanism: potent oral estrogen. archivesofmedicalscience.com
Testosterone therapy (selected adults with CAIS post-gonadectomy) – emerging evidence shows testosterone may be non-inferior to estradiol for quality of life and yields similar estradiol levels via aromatization; used when patients prefer. Doses individualized (e.g., transdermal). Purpose: symptom control and well-being. Mechanism: aromatization to estradiol; limited AR action in CAIS. SpringerLink
Topical dihydrotestosterone (DHT) gel – in some PAIS assigned-male infants/children to address micropenis before surgery or at puberty. Purpose: local androgen effect. Mechanism: non-aromatizable androgen acting on partially responsive tissues. Evidence is limited and case-based. NCBI
Testosterone (systemic) in PAIS assigned male – supports pubertal virilization where tissues retain partial sensitivity. Purpose: develop secondary male traits. Mechanism: AR stimulation where functional. NCBI
Vaginal estrogen cream – short-term adjunct to improve comfort with dilation/intercourse if tissues are dry or fragile. Purpose: local comfort. Mechanism: local mucosal trophic effects. ACOG
Calcium supplementation – only if intake is below targets after a food-first approach. Typical total daily calcium (food + supplements) 1,000–1,200 mg depending on age/sex. Purpose: bone mineral support. Mechanism: mineral substrate. Bone Health & Osteoporosis Foundation
Vitamin D3 supplementation – dose per guideline (often 400–1,000 IU/day in healthy adults; higher in selected groups); check local policy. Purpose: enhance calcium absorption and bone health. Mechanism: 25(OH)D sufficiency. Endocrine Society+1
Bisphosphonates (e.g., alendronate) – considered for confirmed osteoporosis/fracture risk after specialist review; not first-line for otherwise healthy young adults if HRT is optimized. Purpose: reduce fracture risk. Mechanism: inhibit bone resorption. PMC
Denosumab – specialist option for high-risk osteoporosis when indicated. Purpose: fracture prevention. Mechanism: RANKL inhibition. PMC
Selective estrogen receptor modulators (SERMs) – niche use in bone health; balance risks/benefits; not routine in AIS. Purpose: bone density support in selected cases. Mechanism: ER agonism in bone. PMC
Analgesics (short-term) – for post-op or dilation-related pain per general standards. Purpose: comfort. Mechanism: nociception modulation. NCBI
Topical lubricants/moisturizers – non-hormonal products to reduce friction and dryness during dilation or sex. Purpose: comfort and tissue protection. Mechanism: barrier and hydration. ACOG
GnRH analogues – not routine for CAIS; in selected PAIS scenarios may be used to modulate puberty timing or symptoms, under specialist care. Purpose: tailored endocrine control. Mechanism: pituitary down-regulation. NCBI
Anti-androgens – generally not useful in CAIS (receptor nonfunctional); very selective PAIS scenarios may consider them for symptom control, but they are not standard. Purpose: reduce androgen effects when unwanted. Mechanism: AR blockade. NCBI
Iron and B12 (if deficient) – treat documented deficiencies that worsen fatigue; not AIS-specific. Purpose: correct anemia and energy. Mechanism: replace nutrient deficits. Office of Dietary Supplements
Psychotropic meds – only if clinically indicated for co-existing anxiety/depression; psychotherapy remains first-line. Purpose: mental health support. Mechanism: neurotransmitter modulation. NCBI
All medications are individualized – choices depend on age, anatomy, goals, tumor-risk decisions, bone status, and side-effect profiles. Purpose: person-centered safety. Mechanism: shared decision-making. Oxford Academic
Note on progesterone: In CAIS there is no uterus, so routine progesterone is not required; some publications discuss combined therapy, but there’s no clear benefit and potential downsides—most expert sources use estradiol alone. PMC+2MDPI+2
Dietary molecular supplements
Vitamin D3 (cholecalciferol): supports calcium absorption and bone mineralization; dose per guideline and blood levels. Endocrine Society+1
Calcium (as citrate/carbonate): fill gaps to reach total daily targets (usually 1,000–1,200 mg/day from diet + pills). Take with food if carbonate. Bone Health & Osteoporosis Foundation
Protein (whey/food): adequate protein helps bone and muscle; aim for balanced intake via diet, supplement only if dietary intake is low. NIAMS
Magnesium: co-factor in bone metabolism; emphasize dietary sources (nuts/greens), supplement only for proven shortfall. Office of Dietary Supplements
Vitamin K (esp. K2): supports bone proteins; prioritize leafy greens/fermented foods; supplements considered case-by-case. Office of Dietary Supplements
Omega-3 (fish oil): general anti-inflammatory benefits; food (fatty fish) preferred; consider capsules if intake is low. World Health Organization
B12 & Folate: correct documented deficiencies affecting energy and homocysteine (bone risk factor); common in restricted diets. Office of Dietary Supplements
Zinc: supports general health; avoid high-dose chronic supplements; emphasize diet first. Office of Dietary Supplements
Boron (trace): possible role in mineral metabolism; keep to dietary sources; supplements only with specialist advice. Office of Dietary Supplements
Electrolyte-balanced hydration: not a pill, but maintaining calcium/sodium balance and avoiding excess soda may help bone. Bone Health & Osteoporosis Foundation
Immunity-booster / regenerative / stem-cell drugs
There are no approved immune-booster, regenerative, or stem-cell drugs for AIS. AIS is due to an AR gene receptor problem; there is currently no gene repair, stem-cell, or regenerative medicine proven to restore AR function in humans. Management remains supportive (hormones, counseling, selective surgery, bone care). Promising basic research exists, but no clinical therapy of this kind is available—using unproven products can be risky and expensive. Safer alternatives are the non-pharmacologic and hormone options above, delivered by a DSD-experienced team. Wikipedia+1
Surgeries
Gonadectomy (orchiectomy) – removal of undescended testes after puberty in many CAIS patients, or earlier in selected cases, to address age-rising tumor risk and personal preference. Risks and timing are individualized; some choose surveillance instead. e-apem.org
Hernia repair ± gonad management – repairs inguinal hernias; gonads may be removed, repositioned (orchiopexy), or left with surveillance depending on plans and risk. Children’s Hospital of Philadelphia
Vaginal surgery (neovaginoplasty) – usually not first-line because dilation works in >90–96%; surgery is reserved for those who prefer it or do not succeed with dilation, with ongoing dilation post-op. ACOG
Hypospadias and genital reconstruction (PAIS, assigned male) – staged procedures to improve urinary/sexual function and match individual goals; timing is carefully discussed. NCBI
Chest surgery (rare in PAIS males with severe gynecomastia) – reduction mammoplasty if significant symptoms persist. NCBI
Practical preventions
Keep hormone therapy optimized after gonadectomy to protect bones and well-being. PMC
Regular bone health plan: exercise, calcium/vitamin D, and DXA scans when advised. PMC+1
Smoking cessation & limit alcohol to reduce bone loss. PMC
Shared decision-making for any surgery—no rushed procedures. Oxford Academic
Cancer-risk conversations and, if retaining gonads, agreed surveillance plan. PMC
Injury/fall prevention during exercise; use progressive resistance with instruction. NIAMS
Sexual-health literacy (lubrication, consent, STIs) and pelvic physiotherapy if pain arises. ACOG
Vaccinations and routine primary care like anyone else. NCBI
Mental-health and peer support for resilience and coping. NCBI
Keep personal medical summary for ER or travel. Oxford Academic
When to see a doctor
New groin/abdominal mass, pain, or swelling if you have undescended gonads or retained testes. PMC
Unexplained bleeding, fever, or severe pelvic pain after dilation or surgery. ACOG
Hot flashes, night sweats, mood changes, low energy, or bone pain if you’ve had gonadectomy—may signal estrogen under-replacement. PMC
Before starting or changing hormones/supplements, to tailor doses safely. The Lancet
Any mental-health concerns (anxiety, depression, relationship stress). NCBI
What to eat & what to avoid
Emphasize: calcium-rich foods (dairy, tofu set with calcium, leafy greens), vitamin-D sources (oily fish, fortified foods), adequate protein (eggs, fish, legumes), and a colorful plant-forward pattern for heart and gut health. Limit alcohol, excess sodium, and sugar-sweetened beverages; avoid smoking. Most people should meet calcium needs from food and add vitamin D only as needed per guideline. Bone Health & Osteoporosis Foundation+1
FAQs
1) Is AIS the same as “testicular feminization”?
Yes—“testicular feminization” is the old name; today we use androgen insensitivity syndrome (AIS). Cleveland Clinic
2) Can AIS be cured?
No curative gene or receptor fix exists yet; treatment focuses on hormones, selective surgery, and supportive care. Wikipedia
3) Do people with CAIS need periods or progesterone?
No uterus = no periods and no routine progesterone requirement. PMC+1
4) Is gonad removal always required?
Not always. Prepubertal risk is low in CAIS; many defer until after puberty. Others choose surveillance. Decisions are shared and individualized. e-apem.org
5) Can someone with CAIS get pregnant?
No eggs and no uterus, so pregnancy is not possible; family-building options include adoption or gestational carrier with donor oocytes. PubMed
6) Why is bone health a big topic in AIS?
Some people with AIS have low bone mineral density, especially if estrogen is inadequate or gonads were removed without proper HRT. PMC
7) Which estrogen is best?
Most centers favor 17β-estradiol (patch or oral). Routes are individualized; transdermal can have metabolic advantages. The Lancet
8) Can testosterone be used after gonadectomy in CAIS?
Some adults prefer testosterone, and trials suggest similar quality of life vs estradiol (aromatization produces estradiol). It’s a valid, shared decision. SpringerLink
9) Does dilation hurt?
With good teaching, lubricants, and pacing, most people succeed and can keep discomfort low; surgery is second-line. ACOG
10) What about hair patterns?
Sparse pubic/axillary hair is typical in CAIS because hair follicles need androgens. This is normal and harmless. MedlinePlus
11) Is gender identity predictable in AIS?
Most with CAIS are raised female and identify as women, but identity is personal. Care is supportive and non-coercive. Oxford Academic
12) Are there cancer screening tests if I keep my gonads?
Teams may offer periodic exam and imaging; there’s no perfect test, so decisions weigh benefits and burdens. PMC
13) Do supplements replace hormones?
No. Calcium/vitamin D support bone, but do not replace estrogen’s key role after gonadectomy. PMC
14) Can surgery “create” a uterus?
No. Surgery can create a vaginal canal if desired, but it cannot create a functioning uterus. ACOG
15) Where can I read more?
Authoritative overviews: GeneReviews, MedlinePlus Genetics, Endotext, and the Endocrine Society guidance for DSD care. Oxford Academic+3NCBI+3MedlinePlus+3
Disclaimer: Each person’s journey is unique, treatment plan, life style, food habit, hormonal condition, immune system, chronic disease condition, geological location, weather and previous medical history is also unique. So always seek the best advice from a qualified medical professional or health care provider before trying any treatments to ensure to find out the best plan for you. This guide is for general information and educational purposes only. Regular check-ups and awareness can help to manage and prevent complications associated with these diseases conditions. If you or someone are suffering from this disease condition bookmark this website or share with someone who might find it useful! Boost your knowledge and stay ahead in your health journey. We always try to ensure that the content is regularly updated to reflect the latest medical research and treatment options. Thank you for giving your valuable time to read the article.
The article is written by Team RxHarun and reviewed by the Rx Editorial Board Members
Last Updated: September 17, 2025.
